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Dear Editor,
We read with interest the article by Arababadi et al. 
(1), which highlights diﬀerent and important areas of 
concern in the management of occult hepatitis B (OBI). 
There are two relevant issues worthy of discussion. First, 
the authors described the variable prevalence of OBI in 
diﬀerent geographical regions worldwide. The labora-
tory assay used to detect OBI is an important determi-
nant of its prevalence. Because of the low viremic state 
of patients, OBI may not be detected even when sensitive 
polymerase chain reaction (PCR) assays are employed. 
Results of a recent population study in our locality in-
volving 13,034 blood donors showed the prevalence of 
OBI to be between 0.11% and 0.13% (2). We used nucleic 
acid testing to detect hepatitis B virus (HBV) DNA, which 
has a detection limit (3.7 IU/mL) lower than that of most 
available PCR assays. Only studies using sensitive assays 
should be considered when implementing policies for 
screening blood donors. Although Arababadi et al. have 
suggested using an antibody against the hepatitis B core 
antigen (anti-HBc) for screening blood donors, there 
is a vast diﬀerence in the prevalence of serum anti-HBc 
positivity and OBI worldwide. For example, the preva-
lence of anti-HBc positivity in Korea is 13.5%, whereas the 
prevalence of OBI in the same region is 0.016% (3). Hence, 
in blood donor screening programs, hepatitis B surface 
antigen (HBsAg) testing followed by nucleic acid testing 
should be regarded as the most accurate approach for 
the detection of OBI. 
Second, the authors have suggested that OBI is a pos-
sible risk factor for hepatocellular carcinoma (HCC), but 
they have also commented that the underlying patho-
genesis is unclear. Recently, an Asian study compared 
the tumorous and adjacent non-tumorous liver tissues 
from 33 cases of cryptogenic HCC and 28 of HCC with 
identiﬁable causes (4). Both intrahepatic HBV DNA and 
HBV pregenomic RNA (pgRNA) were detected in 73% of 
the cases of cryptogenic HCC, albeit at levels lower than 
those detected in cases of HBV-related HCC. Hence, it is 
very likely that both persistent viral replication and viral 
integration play an important role in the pathogenesis 
of OBI-related HCC. The detection rate of intrahepatic 
HBV DNA was higher in the non-tumorous tissues than in 
the tumorous tissues; this ﬁnding is consistent with the 
hypothesis that tumorous tissues lack the optimal envi-
ronment for HBV replication (5), which may aﬀect the 
detection of OBI-related HCC. Therefore, in regions with 
a high prevalence of chronic hepatitis B, OBI should be 
considered as a possible cause of cryptogenic HCC even 
when HBV virologic markers are undetectable in tumor 
histological analysis.848
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